ANGIODYNAMICS, INC.
AngioDynamics, Inc. is a Delaware corporation whose common stock is listed on the Nasdaq Global Select Market under the ticker symbol ANGO. The company is headquartered at 14 Plaza Drive, Latham, New York, with manufacturing operations centered in Queensbury, New York.
AngioDynamics designs, develops, manufactures and markets medical, surgical and diagnostic devices used by physicians in the treatment of peripheral vascular disease, venous disease, oncology and related conditions. The company reports its business through two segments. Its Med Tech segment includes the Auryon atherectomy system for peripheral arterial disease, the AngioVac and AlphaVac mechanical thrombectomy systems, and the NanoKnife irreversible-electroporation ablation system used in oncology and surgical settings. Its Med Device segment covers peripheral intervention products such as angiographic catheters, guidewires and drainage catheters, implantable ports for central venous access, the VenaCure EVLT laser system for venous insufficiency, microwave ablation devices, and endorectal/vaginal balloon products. Products are sold to hospitals, outpatient centers and physician offices in the United States and in international markets served directly and through the company’s foreign subsidiaries.
For the fiscal year ended May 31, 2025, AngioDynamics reported consolidated net sales of $292.7 million, an increase of 8.1% from $270.7 million in the prior fiscal year, with growth concentrated in the Med Tech segment. AngioDynamics’ fiscal 2026 guidance, updated alongside its first-quarter fiscal 2026 results, projected net sales of $308-$313 million for the current fiscal year.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
1
Shareholders of AngioDynamics, Inc.
AngioDynamics, Inc. is a widely held public company listed on the Nasdaq Global Select Market, with a shareholder base composed of institutional and retail investors rather than a small number of private holders. Based on the beneficial ownership table in the company’s definitive proxy statement (DEF 14A) filed September 25, 2025, and on Schedule 13G/13G-A filings made directly with the SEC, the largest disclosed holders as of their respective filing dates were: Divisadero Street Capital Management, LP (8.3%); BlackRock, Inc. (7.1% per the proxy statement; a Schedule 13G/A filed by BlackRock separately reported 7.2% of the class as of the event date March 31, 2025); Systematic Financial Management LP (6.1%); Millennium Management LLC (5.2%); and Point72 Asset Management, L.P. (5.2%). These are institutional investment managers reporting under Schedule 13G, which is used for passive holdings rather than control positions. SEC rules require disclosure only of beneficial owners exceeding 5% of the outstanding class, so AngioDynamics’ full shareholder register includes many additional institutional and individual holders below that threshold that are not individually identified in public filings.
Ultimate beneficial ownership
No natural-person ultimate beneficial owner is disclosed for AngioDynamics, Inc. This is typical for a widely held Nasdaq-listed public company, where ownership is dispersed among institutional asset managers and public shareholders and no individual meets a beneficial-ownership disclosure threshold.
Data availability
Shareholder information for this company is classified as Major shareholders only: only beneficial owners exceeding the 5% SEC disclosure threshold are individually identified in public filings.
Sources
- AngioDynamics, Inc., Definitive Proxy Statement (DEF 14A), filed September 25, 2025, https://www.sec.gov/Archives/edgar/data/1275187/000162828025042704/ango-20250925.htm, retrieved 2026-09-18
- BlackRock, Inc., Schedule 13G/A (Amendment No. 8), event date March 31, 2025, https://www.sec.gov/Archives/edgar/data/0001275187/000157641925000552/primary_doc.xml, retrieved 2026-09-18
| Shareholder | Type | Holding | Source Document |
|---|---|---|---|
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.4% | New York Department of State — Division of Corporations |
Officers
5
Directors and officers of AngioDynamics, Inc.
Per AngioDynamics’ definitive proxy statement (DEF 14A) filed September 25, 2025, the company’s named executive officers are James C. Clemmer, President and Chief Executive Officer; Stephen A. Trowbridge, Executive Vice President and Chief Financial Officer; Lawrence T. Weiss, Senior Vice President, Chief Legal Officer and Corporate Secretary; Laura Piccinini, Senior Vice President and General Manager, Cardiovascular and International; and Warren G. Nighan, Senior Vice President, Global Supply Chain, Quality and Regulatory Affairs. The Board of Directors comprises eight members: James C. Clemmer (President and CEO, not independent); Howard W. Donnelly (Independent, Board Chairman); Eileen O. Auen; Lorinda A. Burgess; Wesley E. Johnson, Jr.; Karen A. Licitra; Jan Stern Reed; and Michael E. Tarnoff, MD (all independent). The proxy statement does not disclose the nationality or country of residence of any officer or director, consistent with standard US public-company disclosure practice.
Data availability
Officer and director information is classified as Current only: the September 25, 2025 proxy statement discloses the company’s current named executive officers and board of directors as of that filing date, but does not itemize historical appointment dates, former officers, nationality or country of residence.
Sources
- AngioDynamics, Inc., Definitive Proxy Statement (DEF 14A), filed September 25, 2025, https://www.sec.gov/Archives/edgar/data/1275187/000162828025042704/ango-20250925.htm, retrieved 2026-09-18
Group Structure
Group structure of AngioDynamics, Inc.
AngioDynamics, Inc. is the ultimate parent company of its corporate group; it is an independent, publicly traded Nasdaq-listed corporation and is not itself a subsidiary of another company. Based on Exhibit 21.1 to its Form 10-K for the fiscal year ended May 31, 2025, filed with the SEC, the company has verified direct or indirect subsidiaries incorporated in the United Kingdom, the Netherlands, France, Canada, Brazil, Israel, Italy, and Delaware (United States). The structure reflects the group’s international sales, marketing and distribution operations alongside its principal New York corporate and manufacturing base. Exhibit 21.1 does not break out individual ownership percentages for these subsidiaries. Information is current as of the FY2025 Form 10-K filing.
Verified corporate relationships
| Entity | Country | Registration number | Relationship | Ownership | Status | Information date |
|---|---|---|---|---|---|---|
| RITA Medical Systems, LLC | United States (Delaware) | Not independently confirmed | Direct or indirect subsidiary | Ownership percentage not disclosed | Active | 2025-05-31 |
| AngioDynamics UK Limited | United Kingdom | Not independently confirmed | Direct or indirect subsidiary | Ownership percentage not disclosed | Active | 2025-05-31 |
| AngioDynamics Netherlands B.V. | Netherlands | Not independently confirmed | Direct or indirect subsidiary | Ownership percentage not disclosed | Active | 2025-05-31 |
| AngioDynamics France, SARL | France | Not independently confirmed | Direct or indirect subsidiary | Ownership percentage not disclosed | Active | 2025-05-31 |
| AngioDynamics Canada Inc. | Canada | Not independently confirmed | Direct or indirect subsidiary | Ownership percentage not disclosed | Active | 2025-05-31 |
| AngioDynamics Medical Brasil Servicos de Marketing Ltda. | Brazil | Not independently confirmed | Direct or indirect subsidiary | Ownership percentage not disclosed | Active | 2025-05-31 |
| Eximo Medical, Ltd. | Israel | Not independently confirmed | Direct or indirect subsidiary | Ownership percentage not disclosed | Active | 2025-05-31 |
| AngioDynamics Italy S.r.l | Italy | Not independently confirmed | Direct or indirect subsidiary | Ownership percentage not disclosed | Active | 2025-05-31 |
Data availability
Corporate-linkage information for this company is classified as Subsidiaries only: Exhibit 21.1 to the FY2025 Form 10-K lists the company’s subsidiaries but does not disclose individual ownership percentages, and as a Nasdaq-listed public company AngioDynamics has no parent entity to report.
Sources
- AngioDynamics, Inc., Form 10-K for the fiscal year ended May 31, 2025, Exhibit 21.1 (List of Subsidiaries), https://www.sec.gov/Archives/edgar/data/1275187/000127518725000014/ex2105312025.htm, retrieved 2026-09-18
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
What does ANGIODYNAMICS, INC. do?
US medical device company (Nasdaq: ANGO) designing and manufacturing vascular access, oncology, peripheral vascular and surgical devices through its Med Tech and Med Device segments, including the Auryon atherectomy system, AngioVac/AlphaVac thrombectomy systems and NanoKnife ablation system.
Who owns ANGIODYNAMICS, INC.?
Widely held public company; largest disclosed 5%+ holders per the September 2025 proxy statement are Divisadero Street Capital Management (8.3%), BlackRock (7.1%), Systematic Financial Management (6.1%), Millennium Management (5.2%) and Point72 Asset Management (5.2%).
Who is ANGIODYNAMICS, INC.'s UBO (Ultimate Beneficial Owner)?
No natural-person ultimate beneficial owner disclosed; typical for a widely held Nasdaq-listed company.
What is ANGIODYNAMICS, INC.'s company registration number?
ANGIODYNAMICS, INC.'s registration number is 2103533, filed with New York Department of State — Division of Corporations in United States. Its current status on the register is active.
Is ANGIODYNAMICS, INC. still an active company?
ANGIODYNAMICS, INC.'s status on New York Department of State — Division of Corporations is listed as active.
When was ANGIODYNAMICS, INC. incorporated?
ANGIODYNAMICS, INC. was incorporated on 17 January 1997, according to New York Department of State — Division of Corporations.
What is ANGIODYNAMICS, INC.'s registered address?
The registered address on file for ANGIODYNAMICS, INC. is Latham, United States.
What legal structure is ANGIODYNAMICS, INC. registered as?
ANGIODYNAMICS, INC. is registered as a Private limited company (Ltd.) in United States.
What is ANGIODYNAMICS, INC.'s revenue?
Consolidated net sales of $292.7 million for the fiscal year ended May 31, 2025, up 8.1% from $270.7 million the prior year.
Is ANGIODYNAMICS, INC. listed on a stock exchange?
Listed on the Nasdaq Global Select Market under ticker ANGO; incorporated in Delaware.
Who are the officers/directors of ANGIODYNAMICS, INC.?
CEO James C. Clemmer, CFO Stephen A. Trowbridge and Chief Legal Officer Lawrence T. Weiss lead management; board chaired by independent director Howard W. Donnelly.
Does ANGIODYNAMICS, INC. have a parent company or subsidiaries?
Ultimate parent of its own group; verified subsidiaries in the UK, Netherlands, France, Canada, Brazil, Israel, Italy and Delaware per the FY2025 10-K, Exhibit 21.1.
Can Zavia monitor changes to ANGIODYNAMICS, INC.'s ownership over time?
This profile reflects a point-in-time snapshot from New York Department of State — Division of Corporations. Zavia's monitoring API can track changes to ANGIODYNAMICS, INC.'s registered shareholders, officers, and group structure going forward, flagging updates as they're filed rather than requiring a manual recheck.
Can I access ANGIODYNAMICS, INC.'s data through an API?
Yes. Zavia's API connects directly to official government ownership registries across 195 countries and territories, including United States, so records like ANGIODYNAMICS, INC.'s registration, shareholder, UBO, and group-structure data can be queried programmatically instead of viewed one page at a time.
Where does this company information come from, and how current is it?
This record is sourced directly from New York Department of State — Division of Corporations and was last synced on 18 September 2026.